Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Myriad Genetics, Inc.NASDAQ: MYGN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $34.1M (cash outflow) rose 34000.0% year over year, ahead of the +294.4% change in trailing-twelve-month net income. Sequentially, it rose 331.6% from the prior quarter. Over 3 fiscal years it compounded at +48.4% a year.
Context
- Net income amounted to 44.4% of revenue in FY2025, up 29.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$66.04M (-82.0%) for the fiscal year ending Dec 2026, a slowdown from the +187.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$34.1M+331.6% QoQ
- Last fiscal yearDec 2025
- -$365.9M+187.4% YoY
- LTMMar 2026
- -$399.9M+294.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (365.9M) USD
- Year-over-year change
- -187.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (365.9M) | -187.4% |
| FY2024 | 2024-12-31 | (127.3M) | +51.7% |
| FY2023 | 2023-12-31 | (263.3M) | -135.1% |
| FY2022 | 2022-12-31 | (112M) | -311.8% |
| FY2021 | 2021-12-31 | (27.2M) | — |
Net Income vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 net income of $399.9M is the 3rd largest of the 10 companies compared; the peer median is $51.88M.
- Its year-over-year change of +294.4% is the 2nd highest of 9, against a peer median of +11.6%.
- Net income amounts to 48.2% of revenue for MYGN, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $485.07M | +21.6% | -14.0% | 37.9% | |
| LTM Jun 2026 | $409.32M | +9.6% | +0.1% | 19.5% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
| LTM Jun 2026 | $114.48M | +334.7% | — | 20.4% | |
| LTM Mar 2026 | $95.55M | +13.7% | -10.5% | 148.1% | |
| LTM Mar 2026 | $74.56M | +78.1% | — | 23.3% | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $47.84M | -17.8% | -11.7% | 2454.6% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.71M | — | — | 9.5% |
| Peer median (excluding MYGN) | $51.88M | +11.6% | -11.1% | 20.4% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| Deferred Income Tax | (34.7M) | (31.9M) | (600K) | (300K) | (32.4M) |
| Stock-Based Compensation | 36.3M | 38.1M | 40.7M | 49.8M | 35.2M |
| Change in Working Capital | 120.8M | (83.5M) | 27M | (54.4M) | (19.3M) |
| Accounts Receivables | (8.8M) | 7.7M | 3.8M | (8.7M) | 6.2M |
| Inventory | 1.6M | (2.9M) | (1.8M) | (6.2M) | (3.2M) |
| Accounts Payables | 9.2M | (3.5M) | (3.7M) | 4.7M | (1.4M) |
| Other Working Capital | 118.8M | (84.8M) | 28.7M | (44.2M) | (20.9M) |
| Other Non-Cash Items | (139.4M) | 30.3M | 23.4M | 62.3M | 21.1M |
| Operating Cash Flow | 18.6M | (106.3M) | (110.9M) | (8.7M) | 1.8M |
| Capital Expenditures | (18M) | (45.3M) | (73.3M) | (29.7M) | (15.6M) |
| Acquisitions (Net) | 379.1M | (57.2M) | 0 | 8.8M | 0 |
| Purchases of Investments | (147.8M) | (103.2M) | 0 | 0 | 0 |
| Sales of Investments | 61.1M | 128.2M | 105.2M | 9M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 274.4M | (77.5M) | 31.9M | (11.9M) | (27.4M) |
| Debt Repayment | (226.4M) | — | 39.8M | 100K | 75.9M |
| Common Stock Issued | 0 | 0 | 117.6M | 0 | 3.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75.8M | (8M) | (4.5M) | (7.5M) | (15M) |
| Financing Cash Flow | (150.6M) | (8M) | 152.9M | (7.4M) | 64.2M |
| Effect of Forex Changes | (600K) | (600K) | 600K | (1M) | 800K |
| Net Change in Cash | 141.8M | (192.4M) | 74.5M | (29M) | 39.4M |
| Free Cash Flow | 600K | (151.6M) | (184.2M) | (38.4M) | (13.8M) |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.